Skip to main content
Top

Open Access 25-04-2024 | Original Paper

Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation

Authors: Clara Mukuria, Matthew Franklin, Sebastian Hinde

Published in: The European Journal of Health Economics

Login to get access

Abstract

Purpose

Generic preferenced-based measures, such as EQ-5D-3L, that are used to estimate quality adjusted life years (QALYs) for economic evaluation are not always available in clinical trials. Predicting EQ-5D-3L values from the commonly used Patient Health Questionnaire 9 (PHQ-9) and Generalised Anxiety Disorder-7 (GAD-7) would allow estimation of QALYs from such trials. The aim was to provide mapping functions to estimate EQ-5D-3L from PHQ-9 and GAD-7 to facilitate economic evaluation.

Methods

Data was drawn from four trials of patients with symptoms of depression testing collaborative care or computerised cognitive behavioural therapy. Patients completed PHQ-9, GAD-7, and EQ-5D-3L at different timepoints. Mapping was undertaken using adjusted limited dependent variable mixture models (ALDVMM), ordinary least squares (OLS), and Tobit models based on PHQ-9, GAD-7 scores or questions, and age to predict EQ-5D-3L utilities. Models were selected based on mean error (ME), mean absolute error (MAE), root mean squared error (RMSE), model goodness of fit, and visual inspection of the predictions.

Results

There were 5583 and 3942 observations for EQ-5D-3L combined with PHQ-9 and GAD-7 respectively. ALDVMM models had low ME ( ≤|0.0018|) and MAE ranging from 0.189 to 0.192, while RMSE was from 0.251 to 0.254 and had better predictions than OLS and Tobit models. ALDVMM models with four components based on PHQ-9 and GAD-7 scores are recommended for estimating EQ-5D-3L utilities.

Conclusions

Recommended mapping functions provide users with an approach to estimate EQ-5D-3L utilities for economic evaluation using PHQ-9, GAD-7, or both scores where they have been used together.
Appendix
Available only for authorised users
Literature
1.
go back to reference National Institute of Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. (2022) NICE. National Institute of Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. (2022) NICE.
2.
go back to reference Brazier, J., Ratcliffe, J., Saloman, J., Tsuchiya, A.: Measuring and valuing health benefits for economic evaluation. Oxford University Press, UK (2017) Brazier, J., Ratcliffe, J., Saloman, J., Tsuchiya, A.: Measuring and valuing health benefits for economic evaluation. Oxford University Press, UK (2017)
4.
go back to reference Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., Busschbach, J., Boye, K.S.: Which multi-attribute utility instruments are recommended for use in cost-utility analysis? a review of national health technology assessment (HTA) guidelines. Eur. J. Health Econ. 21(8), 1245–1257 (2020)CrossRefPubMedPubMedCentral Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., Busschbach, J., Boye, K.S.: Which multi-attribute utility instruments are recommended for use in cost-utility analysis? a review of national health technology assessment (HTA) guidelines. Eur. J. Health Econ. 21(8), 1245–1257 (2020)CrossRefPubMedPubMedCentral
5.
go back to reference Kroenke, K., Spitzer, R.L., Williams, J.B.: The PHQ-9: validity of a brief depression severity measure. Journal Gen Intern Med 16, 606–613 (2001)CrossRef Kroenke, K., Spitzer, R.L., Williams, J.B.: The PHQ-9: validity of a brief depression severity measure. Journal Gen Intern Med 16, 606–613 (2001)CrossRef
6.
go back to reference Spitzer, R.L., Kroenke, K., Williams, J.B., Löwe, B.: A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Intern. Med. 166(10), 1092–1097 (2006)CrossRefPubMed Spitzer, R.L., Kroenke, K., Williams, J.B., Löwe, B.: A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Intern. Med. 166(10), 1092–1097 (2006)CrossRefPubMed
7.
go back to reference Mukuria, C., Rowen, D., Harnan, S., Rawdin, A., Wong, R., Ara, R., Brazier, J.: An updated systematic review of studies mapping (or cross-walking) measures of health-related quality of life to generic preference-based measures to generate utility values. Appl. Health Econ. Health Policy 17, 295–313 (2019)CrossRefPubMed Mukuria, C., Rowen, D., Harnan, S., Rawdin, A., Wong, R., Ara, R., Brazier, J.: An updated systematic review of studies mapping (or cross-walking) measures of health-related quality of life to generic preference-based measures to generate utility values. Appl. Health Econ. Health Policy 17, 295–313 (2019)CrossRefPubMed
8.
go back to reference Brazier, J., Connell, J., Papaioannou, D., Mukuria, C., Mulhern, B., Peasgood, T., Jones, M.L., Paisley, S., O’Cathain, A., Barkham, M., Knapp, M.: A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol. Assess. 18(34), vii (2014)CrossRefPubMedPubMedCentral Brazier, J., Connell, J., Papaioannou, D., Mukuria, C., Mulhern, B., Peasgood, T., Jones, M.L., Paisley, S., O’Cathain, A., Barkham, M., Knapp, M.: A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol. Assess. 18(34), vii (2014)CrossRefPubMedPubMedCentral
9.
go back to reference Wailoo, A.J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., Botteman, M., Busschbach, J.: Mapping to estimate health-state utility from non–preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value in Health. 20(1), 18–27 (2017)CrossRefPubMed Wailoo, A.J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., Botteman, M., Busschbach, J.: Mapping to estimate health-state utility from non–preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value in Health. 20(1), 18–27 (2017)CrossRefPubMed
10.
go back to reference Hernandez Alava, M.H., Wailoo, A.J., Ara, R.: Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utilities. Value in Health. 15(3), 550–561 (2012)CrossRefPubMed Hernandez Alava, M.H., Wailoo, A.J., Ara, R.: Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utilities. Value in Health. 15(3), 550–561 (2012)CrossRefPubMed
11.
go back to reference Furukawa, T.A., Levine, S.Z., Buntrock, C., Ebert, D.D., Gilbody, S., Brabyn, S., Kessler, D., Björkelund, C., Eriksson, M., Kleiboer, A., Van Straten, A.: How can we estimate QALYs based on PHQ-9 scores? Equipercentile linking analysis of PHQ-9 and EQ-5D. Evid. Based Ment. Health. Based Ment. Health. 24(3), 97–101 (2021)CrossRef Furukawa, T.A., Levine, S.Z., Buntrock, C., Ebert, D.D., Gilbody, S., Brabyn, S., Kessler, D., Björkelund, C., Eriksson, M., Kleiboer, A., Van Straten, A.: How can we estimate QALYs based on PHQ-9 scores? Equipercentile linking analysis of PHQ-9 and EQ-5D. Evid. Based Ment. Health. Based Ment. Health. 24(3), 97–101 (2021)CrossRef
12.
go back to reference Franklin, M., Young, T.: Correspondence on “how can we estimate QALYs based on PHQ-9 scores? equipercentile linking analysis of PHQ-9 and EQ-5D” by Furukawa et al. Evid. Based Ment. Health. Based Ment. Health. 24(4), e5 (2021)CrossRef Franklin, M., Young, T.: Correspondence on “how can we estimate QALYs based on PHQ-9 scores? equipercentile linking analysis of PHQ-9 and EQ-5D” by Furukawa et al. Evid. Based Ment. Health. Based Ment. Health. 24(4), e5 (2021)CrossRef
13.
go back to reference Franklin, M., Alava, M.H.: Enabling QALY estimation in mental health trials and care settings: mapping from the PHQ-9 and GAD-7 to the ReQoL-UI or EQ-5D-5L using mixture models. Qual. Life Res. 32(10), 2763–2778 (2023)CrossRefPubMedPubMedCentral Franklin, M., Alava, M.H.: Enabling QALY estimation in mental health trials and care settings: mapping from the PHQ-9 and GAD-7 to the ReQoL-UI or EQ-5D-5L using mixture models. Qual. Life Res. 32(10), 2763–2778 (2023)CrossRefPubMedPubMedCentral
14.
go back to reference Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 10, 1727–1736 (2011)CrossRef Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 10, 1727–1736 (2011)CrossRef
15.
go back to reference Lewis, H., Adamson, J., Atherton, K., Bailey, D., Birtwistle, J., Bosanquet, K., Clare, E., Delgadillo, J., Ekers, D., Foster, D., Gabe, R.: CollAborative care and active surveillance for screen-positive elders with subthreshold depression (CASPER): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness. Health Technol. Assess. 21(8), 1 (2017)CrossRefPubMedPubMedCentral Lewis, H., Adamson, J., Atherton, K., Bailey, D., Birtwistle, J., Bosanquet, K., Clare, E., Delgadillo, J., Ekers, D., Foster, D., Gabe, R.: CollAborative care and active surveillance for screen-positive elders with subthreshold depression (CASPER): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness. Health Technol. Assess. 21(8), 1 (2017)CrossRefPubMedPubMedCentral
16.
go back to reference Bosanquet, K., Adamson, J., Atherton, K., Bailey, D., Baxter, C., Beresford-Dent, J., Birtwistle, J., Chew-Graham, C., Clare, E., Delgadillo, J., Ekers, D.: CollAborative care for Screen-Positive EldeRs with major depression (CASPER plus): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness. Health Technol. Assess. 21(67), 1 (2017)CrossRefPubMedPubMedCentral Bosanquet, K., Adamson, J., Atherton, K., Bailey, D., Baxter, C., Beresford-Dent, J., Birtwistle, J., Chew-Graham, C., Clare, E., Delgadillo, J., Ekers, D.: CollAborative care for Screen-Positive EldeRs with major depression (CASPER plus): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness. Health Technol. Assess. 21(67), 1 (2017)CrossRefPubMedPubMedCentral
17.
go back to reference Littlewood, E., Duarte, A., Hewitt, C., Knowles, S., Palmer, S., Walker, S., Andersen, P., Araya, R., Barkham, M., Bower, P., Brabyn, S.: A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) Trial. Health Technol. Assess. 19(101), 1 (2015)CrossRefPubMedCentral Littlewood, E., Duarte, A., Hewitt, C., Knowles, S., Palmer, S., Walker, S., Andersen, P., Araya, R., Barkham, M., Bower, P., Brabyn, S.: A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) Trial. Health Technol. Assess. 19(101), 1 (2015)CrossRefPubMedCentral
18.
go back to reference Brabyn, S., Araya, R., Barkham, M., Bower, P., Cooper, C., Duarte, A., Kessler, D., et al.: The second randomised evaluation of the effectiveness, cost-effectiveness and acceptability of computerised therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? a randomised controlled trial. Health Technol. Assess. 20(89), 1–64 (2016)CrossRefPubMedPubMedCentral Brabyn, S., Araya, R., Barkham, M., Bower, P., Cooper, C., Duarte, A., Kessler, D., et al.: The second randomised evaluation of the effectiveness, cost-effectiveness and acceptability of computerised therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? a randomised controlled trial. Health Technol. Assess. 20(89), 1–64 (2016)CrossRefPubMedPubMedCentral
19.
20.
go back to reference Kroenke, K., Wu, J., Yu, Z., Bair, M.J., Kean, J., Stump, T., Monahan, P.O.: The patient health questionnaire anxiety and depression scale (PHQ-ADS): Initial validation in three clinical trials. Psychosom. Med.. Med. 78(6), 716 (2016)CrossRef Kroenke, K., Wu, J., Yu, Z., Bair, M.J., Kean, J., Stump, T., Monahan, P.O.: The patient health questionnaire anxiety and depression scale (PHQ-ADS): Initial validation in three clinical trials. Psychosom. Med.. Med. 78(6), 716 (2016)CrossRef
21.
go back to reference Kroenke, K., Baye, F., Lourens, S.G.: Comparative validity and responsiveness of PHQ-ADS and other composite anxiety-depression measures. J. Affect. Disord.Disord. 246, 437–443 (2019)CrossRef Kroenke, K., Baye, F., Lourens, S.G.: Comparative validity and responsiveness of PHQ-ADS and other composite anxiety-depression measures. J. Affect. Disord.Disord. 246, 437–443 (2019)CrossRef
22.
go back to reference Cohen, J.: Statistical power analysis. Curr. Dir. Psychol. Sci.. Dir. Psychol. Sci. 1(3), 98–101 (1992)CrossRef Cohen, J.: Statistical power analysis. Curr. Dir. Psychol. Sci.. Dir. Psychol. Sci. 1(3), 98–101 (1992)CrossRef
23.
go back to reference Gray, A.M., Rivero-Arias, O., Clark, P.M.: Estimating the association between SF-12 responses and EQ-5D utilities by response mapping. Med. Decis. Making 26, 18–29 (2006)CrossRefPubMed Gray, A.M., Rivero-Arias, O., Clark, P.M.: Estimating the association between SF-12 responses and EQ-5D utilities by response mapping. Med. Decis. Making 26, 18–29 (2006)CrossRefPubMed
24.
go back to reference Hernandez Alava, M., Wailoo, A., Pudney, S., Gray, L., Manca, A.: Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods. Health Technol. Assess. 24(34), 1 (2020)CrossRefPubMedPubMedCentral Hernandez Alava, M., Wailoo, A., Pudney, S., Gray, L., Manca, A.: Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods. Health Technol. Assess. 24(34), 1 (2020)CrossRefPubMedPubMedCentral
25.
go back to reference Mulhern, B., Mukuria, C., Barkham, M., Knapp, M., Byford, S., Brazier, J.: Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. Br. J. Psychiatry 205(3), 236–243 (2014)CrossRefPubMed Mulhern, B., Mukuria, C., Barkham, M., Knapp, M., Byford, S., Brazier, J.: Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. Br. J. Psychiatry 205(3), 236–243 (2014)CrossRefPubMed
26.
go back to reference Franklin, M., Enrique, A., Palacios, J., Richards, D.: Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsiveness. Qual. Life Res. 30(9), 2633–2647 (2021)CrossRefPubMedPubMedCentral Franklin, M., Enrique, A., Palacios, J., Richards, D.: Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsiveness. Qual. Life Res. 30(9), 2633–2647 (2021)CrossRefPubMedPubMedCentral
Metadata
Title
Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation
Authors
Clara Mukuria
Matthew Franklin
Sebastian Hinde
Publication date
25-04-2024
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-024-01692-0